| 2026-08-03 | 8-K | 10.3 | – Second Amended and Restated Employment Agreement, by and between Supernus Pharmaceuticals, Inc. and Jack A. Khattar, dated as of August 1, 2026 |
|---|
| 2026-08-03 | 8-K | 10.2 | - Form of Voting and Support Agreement, by and between Supernus Pharmaceuticals, Inc. and certain stockholders of Indivior Pharmaceuticals, Inc. party thereto. |
|---|
| 2026-08-03 | 8-K | 10.1 | - Form of Voting and Support Agreement, by and between Indivior Pharmaceuticals, Inc. and certain stockholders of Supernus Pharmaceuticals, Inc. party thereto. |
|---|
| 2026-01-28 | 8-K | 10.1 | First Amendment to Agreement and Plan of Merger, dated as of January 22, 2026, by and among Supernus Pharmaceuticals, Inc. and Reich Consulting Group, Inc. |
|---|
| 2025-08-05 | 10-Q | 10.2 | Form of Amended and Restated Executive Retention Agreement, dated June 6, 2025 |
|---|
| 2025-08-05 | 10-Q | 10.1 | Fifth Amendment to the Amended and Restated Employment Agreement, dated July 10, 2025, by and between the Registrant and Jack Khattar |
|---|
| 2025-07-31 | 8-K | 10.1 | — Contingent Value Rights Agreement, dated as of July 30, 2025, by and among Supernus Pharmaceuticals, Inc. and Equiniti Trust Company, LLC |
|---|
| 2025-02-24 | 8-K | 10.3 | - Form of Performance Share Unit Award Agreement, for awards issued after 2024 under the Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan. |
|---|
| 2024-08-06 | 10-Q | 10.1 | Settlement Agreement, dated as of April 30, 2024, by and between Supernus Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. |
|---|
| 2024-02-27 | 10-K | 10.48 | Settlement Agreement, dated as of June 21, 2023, by and between Supernus Pharmaceuticals, Inc. with Apotex Inc. and Apotex Corp. |
|---|
| 2024-02-27 | 10-K | 10.44 | Form of Performance Share Unit Award Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2024-02-27 | 10-K | 10.42 | Form of Restricted Stock Unit Award Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2024-02-27 | 10-K | 10.40 | Form of Non-Statutory Time-Based Stock Option Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2024-02-27 | 10-K | 10.38 | Form of Time-Based Incentive Stock Option Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2024-02-27 | 10-K | 10.16 | Form of Executive Retention Agreement. |
|---|
| 2023-03-09 | 10-K | 10.71 | Settlement Agreement, dated as of December 31, 2022, by and between Supernus Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited. |
|---|
| 2023-02-14 | 8-K | 10.1 | Credit Line Agreement |
|---|
| 2021-11-05 | 10-Q | 10.1 | Amendment to Deed of Lease, August 23, 2021, by and between Supernus Pharmaceuticals, Inc. and Key West MD Owner, LLC. |
|---|
| 2021-08-06 | 10-Q | 10.6 | Form of Performance Share Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2021-08-06 | 10-Q | 10.5 | Form of Restricted Stock Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2021-08-06 | 10-Q | 10.4 | Form of Non-Statutory Time-Based Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2021-08-06 | 10-Q | 10.3 | Form of Time-Based Incentive Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan. |
|---|
| 2021-08-06 | 10-Q | 10.2 | API Supply Agreement, dated July 13, 2021, by and between Supernus Pharmaceuticals, Inc. and Bachem Americas, Inc. |
|---|
| 2021-08-06 | 10-Q | 10.1 | Commercial Supply Agreement, dated May 12, 2021, by and between Supernus Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC. |
|---|
| 2021-07-29 | 8-K | 10.1 | Exhibit 10.1†+ – Offer Letter to Timothy C. Dec. |
|---|
| 2021-03-08 | 10-K | 10.12 | Purchase and Sale Agreement, dated as of June 9, 2006, by and between the Registrant and Rune HealthCare Limited. |
|---|
| 2021-03-08 | 10-K | 10.11 | Exclusive License Agreement, dated as of June 6, 2006, by and between the Registrant and United Therapeutics Corporation. |
|---|
| 2021-03-08 | 10-K | 10.10 | Guanfacine License Agreement, dated as of December 22, 2005, by and among the Registrant, Shire LLC and Shire plc, as amended. |
|---|
| 2021-03-08 | 10-K | 10.9 | Asset Purchase and Contribution Agreement, dated as of December 22, 2005, by and among the Registrant, Shire Laboratories Inc. and Shire plc. |
|---|
| 2020-11-19 | 8-K | 10.2 | Consulting Agreement between |
|---|
| 2020-11-19 | 8-K | 10.1 | Consulting Agreement between |
|---|
| 2020-10-05 | 8-K | 10.2 | EXECUTIVE RETENTION AGREEMENT |
|---|
| 2020-10-05 | 8-K | 10.1 | ex101jameskellyofferle.htm |
|---|
| 2020-08-17 | 10-Q | 10.5 | Letter Agreement Re: Exclusive Supply of Pens, effective September 23, 2019. |
|---|
| 2020-08-17 | 10-Q | 10.4 | Letter Agreement Re: Memorandum of Understanding for the Supply of Pens, effective February 25, 2019. |
|---|
| 2020-08-17 | 10-Q | 10.3 | First Amendment to Amended and Restated Distribution, Development, Commercialization and Supply Agreement, dated February 19, 2020, by and between Britannia Pharmaceuticals Limited and US WorldMeds, LLC. |
|---|
| 2020-08-17 | 10-Q | 10.2 | Amended and Restated Distribution, Development, Commercialization and Supply Agreement, dated January 15, 2016, by and between Britannia Pharmaceuticals Limited and US WorldMeds, LLC. |
|---|
| 2020-08-17 | 10-Q | 10.1 | Development and Option Agreement, dated April 21, 2020, by and between Navitor Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. |
|---|
| 2020-02-27 | 8-K | 10.2 | Exhibit 10.2+ – Form of Performance Share Unit Award Agreement, issued under the Amended and Restated Stock Incentive Plan, for grants made to Jack A. Khattar, filed herewith as an Exhibit pursuant to Item 1.01 hereof. |
|---|
| 2020-02-27 | 8-K | 10.1 | Exhibit 10.1+ – Form of Restricted Stock Unit Award Agreement for Non-Management Directors, issued under the Supernus Pharmaceuticals, Inc., 2012 Equity Incentive Plan, as amended, for grants made to non-management directors, filed herewith as an Exhibit to Item 1.01 hereof. |
|---|
| 2019-02-05 | 8-K | 10.1 | Lease Agreement Dated January 31, 2019. |
|---|
| 2018-05-11 | 8-K | 10.2 | — Form of Amendment to Executive Retention Agreement. |
|---|
| 2018-05-11 | 8-K | 10.1 | — Third Amendment to Amended and Restated Employment Agreement, dated May 8, 2018, between Supernus Pharmaceuticals, Inc. and Jack Khattar. |
|---|
| 2018-03-20 | 8-K | 10.12 | — Additional Issuer Warrant Transaction, dated March 15, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.11 | — Additional Issuer Warrant Transaction, dated March 15, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.10 | — Additional Issuer Warrant Transaction, dated March 15, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.9 | — Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.8 | — Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.7 | — Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.6 | — Base Issuer Warrant Transaction, dated March 14, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.5 | — Base Issuer Warrant Transaction, dated March 14, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.4 | — Base Issuer Warrant Transaction, dated March 14, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.3 | — Base Convertible Bond Hedge Transaction, dated March 14, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.2 | — Base Convertible Bond Hedge Transaction, dated March 14, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-20 | 8-K | 10.1 | — Base Convertible Bond Hedge Transaction, dated March 14, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc. |
|---|
| 2018-03-05 | 8-K | 10.1 | Lease Agreement Dated February 27, 2018. |
|---|
| 2017-05-09 | 10-Q | 10.3 | Settlement Agreement, dated March 13, 2017, by and between Supernus Pharmaceuticals, Inc., Actavis Laboratories, FL, Inc., Actavis Pharma, Inc., and Watson Laboratories, Inc. |
|---|
| 2017-05-09 | 10-Q | 10.2 | Term Sheet Agreement, dated March 6, 2017, by and between Supernus Pharmaceuticals, Inc., Actavis Laboratories, FL, Inc., Actavis Pharma, Inc., and Watson Laboratories, Inc. |
|---|
| 2017-05-09 | 10-Q | 10.1 | Settlement Agreement, dated March 6, 2017, by and between Supernus Pharmaceuticals, Inc., Zydus Pharmaceutical (USA) Inc., and Cadila Healthcare Limited. |
|---|
| 2016-03-09 | 10-K | 10.36 | ASTERISKS DENOTE OMISSIONS. SETTLEMENT AGREEMENT |
|---|
| 2016-03-04 | 8-K | 10.1 | Second Amendment to the Amended and Restated Employment Agreement, dated March 2, 2016, by and between the Company and Jack Khattar. |
|---|
| 2014-10-24 | 8-K | 10.2 | First Amendment to Lease Agreement. |
|---|
| 2014-10-24 | 8-K | 10.1 | Fourth Amendment to Lease Agreement. |
|---|
| 2014-09-18 | 8-K | 10.1 | Form of Executive Retention Agreement. |
|---|
| 2014-08-11 | 8-K | 10.2 | Amendment to Amended and Restated Employment Agreement, dated August 8, 2014, by and between the Company and Jack Khattar. |
|---|
| 2014-08-11 | 8-K | 10.1 | Form of Executive Retention Agreement. |
|---|
| 2014-07-08 | 8-K | 10.3 | Supernus to Receive $30 Million in Non-Dilutive Royalty Deal |
|---|
| 2014-07-08 | 8-K | 10.2 | Security Agreement, dated July 1, 2014, by and between Supernus Pharmaceuticals, Inc. and HealthCare Royalty Partners III, L.P. |
|---|
| 2014-07-08 | 8-K | 10.1 | Royalty Interest Acquisition Agreement, dated July 1, 2014, by and between Supernus Pharmaceuticals, Inc. and HealthCare Royalty Partners III, L.P. |
|---|
| 2013-08-21 | 8-K | 10.1 | Commercial Supply Agreement, dated December 15, 2012, by and among Attached |
|---|
| 2013-03-15 | 10-K | 10.34 | On January 30, 2013, the Compensation Committee of Supernus Pharmaceuticals, Inc. (the “Company”) approved modifications of the compensation of its executive officers, as follows: |
|---|
| 2013-03-15 | 10-K | 10.33 | LEASE AGREEMENT |
|---|
| 2013-02-07 | 8-K | 10.1 | Commercial Supply Agreement, dated August 23, 2012, by and among Patheon, Inc. and the Company. |
|---|
| 2012-11-02 | 10-Q | 10.3 | Compensatory Arrangements with Executive Officers. |
|---|
| 2012-11-02 | 10-Q | 10.2 | Compensatory Arrangements with Executive Officers. |
|---|
| 2012-11-02 | 10-Q | 10.1 | Offer Letter to Executive Officer. |
|---|